Physician profile
James Redinski
NPI 1326578808
$2,749.82
in general payments reported to CMS, 2019-2025
20 companies · $1,474 in 2025
The $1,474 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.25 · 2020: $17.21 · 2022: $76.26 · 2023: $459 · 2024: $704 · 2025: $1,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,597 · Education: $40.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,596.66 |
| Education | $40.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $607.60 | 2022-2025 | Acthar, Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $395.51 | 2024-2025 | |
| Akebia Therapeutics INC | $346.30 | 2025 | Vafseo |
| Calliditas Therapeutics US INC. | $225.63 | 2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $200.61 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $171.91 | 2024-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $170.69 | 2023-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $95.81 | 2022-2025 | Rayaldee |
| Ardelyx, INC. | $83.03 | 2023-2024 | Ibsrela |
| Aurinia Pharma U.S., INC. | $81.59 | 2023-2024 | Lupkynis |
| Vifor Pharma, INC. | $77.13 | 2023 | Veltassa, Korsuva |
| Lilly USA, LLC | $51.77 | 2024 | Jardiance |
| Merck Sharp & Dohme LLC | $46.21 | 2022-2023 | Verquvo |
| Glaxosmithkline, LLC. | $36.52 | 2025 | Benlysta |
| Amgen INC. | $33.82 | 2024 | Krystexxa, Tavneos |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.14 | 2020-2025 | Jardiance |
| Travere Therapeutics, INC. | $27.79 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $25.82 | 2023 | Onpattro |
| Alexion Pharmaceuticals, INC. | $19.69 | 2023 | Ultomiris |
| Edwards Lifesciences Corporation | $19.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Redinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.